HMCapital co-leads $56m Series B in US pharma firm OncoImmune

HMCapital co-leads $56m Series B in US pharma firm OncoImmune

OncoImmune, Inc., a US-based innovative pharmaceutical firm announced on Thursday that it has garnered $50 million in a Series B round led by HM Capital and an undisclosed blue-chip investor.

New investors GBA Fund and GF Xinde — the PE arm of Hong Kong- and Shenzhen-listed GF Securities, which manages over 30 billion yuan ($4.4 billion) in assets — also participated. Returning backers included China-US healthcare-focused investment firm 3E Bioventures Capital, and Hangzhou-headquartered Kaitai Capital, OncoImmune said on its official website.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter